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MaBACKGROUND Atrioventricular (AV) conduction disturbances requiring permanent pacemaker (PPM) implantation
may complicate transcatheter aortic valve replacement (TAVR). Available evidence on predictors of PPM is sparse
and derived from small studies.
OBJECTIVES The objective of this study was to provide summary effect estimates for clinically useful predictors
of PPM implantation after TAVR.
METHODS We performed a systematic search for studies that reported the incidence of PPM implantation after TAVR
and that provided raw data for the predictors of interest. Data on study, patient, and procedural characteristics were
abstracted. Crude risk ratios (RRs) and 95% conﬁdence intervals for each predictor were calculated by use of random
effects models. Stratiﬁed analyses by type of implanted valve were performed.
RESULTS We obtained data from 41 studies that included 11,210 TAVR patients, of whom 17% required PPM implan-
tation after intervention. The rate of PPM ranged from 2% to 51% in individual studies (with a median of 28% for the
Medtronic CoreValve Revalving System [MCRS] and 6% for the Edwards SAPIEN valve [ESV]). The summary estimates
indicated increased risk of PPM after TAVR for men (RR: 1.23; p < 0.01); for patients with ﬁrst-degree AV block (RR: 1.52;
p < 0.01), left anterior hemiblock (RR: 1.62; p < 0.01), or right bundle branch block (RR: 2.89; p < 0.01) at baseline;
and for patients with intraprocedural AV block (RR: 3.49; p < 0.01). These variables remained signiﬁcant predictors
when only patients treated with the MCRS bioprosthesis were considered. The data for ESV were limited. Unadjusted
estimates indicated a 2.5-fold higher risk for PPM implantation for patients who received the MCRS than for those
who received the ESV.
CONCLUSIONS Male sex, baseline conduction disturbances, and intraprocedural AV block emerged as predictors of
PPM implantation after TAVR. This study provides useful tools to identify high-risk patients and to guide clinical decision
making before and after intervention. (J Am Coll Cardiol 2014;64:129–40) © 2014 by the American College of Cardiology
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130T ranscatheter aortic valve replace-ment (TAVR) has emerged as thetreatment of choice among patients
with symptomatic severe aortic stenosis
deemed inoperable and a valuable treatment
alternative to surgical aortic valve replace-
ment for high-risk surgical patients (1–3). As
a result, the number of patients undergoing
TAVR worldwide has increased steadily, and
the complications related to valve implanta-
tion have been well recognized. Atrioventric-
ular (AV) conduction disturbances requiring
permanent pacemaker (PPM) implantation
are common and clinically important adverse
events (4). Because of the close proximity
of the AV conduction system to the aortic
valvular complex, any intervention (percuta-
neous or surgical) at the valve level may
result in conduction disturbances (5,6).SEE PAGE 141The incidence of AV conduction disturbances as a
result of TAVR and the subsequent requirement forTRATION Previously Identiﬁed Factors Associated
bnormalities After TAVR
d factors associated with conduction abnormalities after
valve replacement (TAVR) fall into 3 broad but often
ries: electrocardiographic, patient, and procedural factors.
ion; AV ¼ atrioventricular; ESV ¼ Edwards SAPIEN Valve;
lar septal; LBBB ¼ left bundle branch block; LVEF ¼ left
fraction; LVOT ¼ left ventricular outﬂow track; MCRS ¼
e Revalving system; PPM ¼ permanent pacemaker;
le branch block.permanent pacing differs between the two most
widely used bioprostheses, the balloon-expandable
Edwards SAPIEN valve (ESV) (Edwards Lifesciences,
Irvine, California) and the self-expandable Medtronic
CoreValve Revalving System (MCRS) (Medtronic,
Minneapolis, Minnesota). PPM implantation in pa-
tients receiving the ESV has been reported at a rate of
between 5% and 12% (7–10), whereas the need for PPM
has been higher with the use of the MCRS (up to 24%
in the FRANCE-2 [French Aortic National CoreValve
and Edwards] registry and 33% in the UK CoreValve
registry) (11,12). Identiﬁcation of high-risk patients
for such complications is of great clinical importance.
For that reason, several patient- and procedure-
related characteristics have been evaluated and pro-
posed as potential predictors; however, available
evidence is limited and inconsistent, mainly derived
from studies of relatively small patient populations
that examined different variables without providing
robust conclusions for their predictive performance.
Therefore, this study sought to provide summary
effect estimates for clinically useful risk predictors
of PPM implantation after TAVR intervention.
METHODS
SEARCH STRATEGY. We performed a broad, comput-
erized literature search of certain text and keywords in
PubMed and EMBASE through October 2013. For our
purposes, we focused only on published data. Our
search was limited to studies in humans, but no lan-
guage or year of publication restrictions were applied.
ELIGIBILITY CRITERIA AND STUDY SELECTION.
We deemed eligible any study of original design
that assessed the incidence of AV conduction or
cardiac rhythm disturbances and the subsequent
need for PPM implantation after TAVR. We included
studies in which quantitative raw data that enabled
the calculation of crude risk ratios (RRs) for the
incidence of PPM implantation for the predictors of
interest were available. When overlapping study
populations (according to participating institutions
and period of patient recruitment) were docu-
mented in different reports, we included the one
with the most recent results and available data of
interest; however, when different predictors were
identiﬁed in reports of overlapping populations,
each predictor was considered eligible and included
separately. Finally, studies that reported outcomes
only for patients with valve-in-valve interventions
and studies of nonoriginal design were not
included.
Two investigators independently conducted the
literature searches, the study eligibility assessment,
PubMed (n=1,983 reports)
EMBASE (n=1,013 reports)
Screening for eligibility in
title and abstract level
536 potentially eligible
reports scrutinized in full-text
Excluded (n=301)
• No outcome of interest (n=300)
• Not retrieved in full-text (n=1)
Excluded (n=194)
• No data available to build 2x2 tables (n=185)
• Overlapping study populations (n=9)
Reference list screening
41 eligible studies
20 different predictors
235 studies reported the
incidence of PPM post-TAVR
FIGURE 1 Study Selection
Flow chart demonstrating the results in each step of the systematic search
to identify studies with available data to calculate crude risk ratios for the
predictors of interest. PPM ¼ permanent pacemaker implantation;
TAVR ¼ transcatheter aortic valve replacement.
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131and the data extraction in duplicate. Any discrep-
ancies were resolved by consensus and arbitration by
a third investigator.
DATA ABSTRACTION. The following study- and
patient-related information was extracted from the
main paper and accompanying supplemental mate-
rial: study design; single or multicenter study; re-
gion and period of patient recruitment; length of
follow-up (given metric); number of participants;
number of PPM implantations after TAVR; age (given
metric); sex (male); baseline procedural risk assess-
ment (by logistic EuroSCORE [European System for
Cardiac Operative Risk Evaluation] or STS-PROM
[Society of Thoracic Surgeons Predicted Risk of
Mortality] score); and the number of patients with
atrial ﬁbrillation (AF), left bundle branch block
(LBBB), or right bundle branch block (RBBB) at
baseline.
Moreover, we extracted information related to pro-
cedural characteristics, including access site (trans-
femoral, transapical, transaortic, trans-subclavian, or
transcarotid) and type of valve prosthesis (MCRS,
ESV, or any other device), in each study. Both de-
vices have received European CE Mark approval,
although only the ESV had received approval from
the U.S. Food and Drug Administration at the time of
our search. When the authors did not clarify the ac-
cess route used for MCRS implantation, we assumed
that all implantations had been performed by the
transfemoral approach. Finally, the indications for
PPM implantation in each study were recorded.
ASSESSED PREDICTORS OF PPM IMPLANTATION.
According to a recently published review (6), we
focused on the following previously proposed pre-
dictors that could be plausibly related to the inter-
vention owing to direct injury to the aortic root: age;
sex (male); baseline (pre-intervention) atrial ﬁbrilla-
tion (any type), ﬁrst-degree AV block, left anterior or
posterior hemiblock, intraprocedural AV block,
LBBB, RBBB, PR interval (>200 ms), QRS duration,
and preserved left ventricular ejection fraction;
increased interventricular septal dimension; smaller
left ventricular outﬂow tract diameter (<21 mm);
access route (femoral vs. subclavian access for MCRS,
arterial vs. apical access for ESV); implantation
depth; MCRS versus ESV; MCRS (vs. ESV) balloon
pre-dilation; larger MCRS prosthesis (>29 mm); and
increased prosthesis-to-annulus size ratio (Central
Illustration).
DATA ANALYSIS. Crude RRs were directly calculated
for each predictor and entered into the primary
analysis. We combined the given data across the
studies using DerSimonian and Laird random effectsmodels (13). Heterogeneity across the studies was
quantiﬁed with the I2 index, which takes values be-
tween 0% and 100%, with values of 25% typically
suggesting low, 50% moderate, and 75% large het-
erogeneity (14). Stratiﬁed analyses were performed
according to the type of implanted valve, whereas
sensitivity analyses were performed after exclusion
of small studies with fewer than 200 patients.
Descriptive characteristics are presented as mean 
standard deviation or median (interquartile range) as
appropriate for continuous variables, whereas cate-
gorical variables are presented as frequencies and
percentages. Patients with prior PPM implantation
unrelated to TAVR were excluded from our analysis,
and each predictor was considered separately. All
reported p values are 2-sided. Statistical analyses
were performed in STATA software (version 12.0,
STATA Corp., College Station, Texas).
RESULTS
INCLUSION OF STUDIES. A total of 2,996 reports
were initially screened in title and abstract level, of
which 536 were retrieved in full text and examined
TABLE 1 Characteristics of the Included Studies
First Author (Ref. #) Year
Study
Design
(Centers) Region(s) Recruitment Period
Follow-Up
(Months)*
Sample
Size
Post-TAVR
PPM
Baseline Characteristics
Age
(yrs) Male
Log
EuroSCORE STS-PROM AF LBBB RBBB
Himbert et al. (15) 2009 Obs.
(single)
France Oct. 2006–Nov. 2008 10 75 4 (5) 82  8 41 (55) 26  13 16  7 ND ND ND
Thielmann et al. (16) 2009 Obs.
(single)
Germany May 2005–Nov. 2008 12 39 4 (10) 81  5 15 (38) 44  13 18  6 ND ND ND
Attias et al. (17) 2010 Obs.
(single)
France Oct. 2006–June 2009 1 83 7 (8) 81  9 44 (53) 26  14 15  8 ND ND ND
Bleiziffer et al. (18) 2010 Obs.
(single)
Germany June 2007–Jan. 2009 0.5 159 44 (28) 81  6 68 (43) 22  13 ND 41 (26) 27 (17) 6 (4)
Eltchaninoff et al. (9) 2010 Obs.
(multi.)
France Feb. 2009–June 2009 1 244 9 (4) 82  7 138 (57) 26  11 19  13 ND ND ND
Baan et al. (19) 2010 Obs.
(single)
Netherlands ND 1 29 7 (24) 80  8 14 (52) ND 5  3 10 (34) 2 (7) 2 (7)
Erkapic et al. (20) 2010 Obs.
(single)
Germany Oct. 2008–Dec. 2009 0.4 50 17 (34) 80  6 23 (46) ND ND 17 (34) 5 (10) 7 (14)
Ewe et al. (21) 2010 Obs.
(multi.)
Netherlands,
Singapore,
Italy
ND 9 147 7 (5) 81  7 63 (43) 22  11 ND 33 (22) ND ND
Ferreira et al. (22) 2010 Obs.
(single)
Portugal Aug. 2007–Oct. 2009 ND 32 8 (25) 81 (76-85) 11 (34) 24 (17-31) ND 9 (28) ND ND
Godino et al. (23) 2010 Obs.
(single)
Italy Nov. 2007–Feb. 2010 6 137 19 (14) 82  6 73 (53) 28  12 7  5 ND ND ND
Haworth et al. (24) 2010 Obs.
(single)
UK 2007–2008 5 33 8 (24) 82  7 20 (57) 24  15 ND 6 (18) 3 (9) 7 (21)
Petronio et al. (25) 2010 Obs.
(multi.)
Italy June 2007–July 2009 6 514 84 (16) 83 (78-86) 226 (44) 20 (13-31) ND ND 60 (12) 40 (8)
Piazza et al. (26) 2010 Obs.
(single)
Netherlands Nov. 2005–April 2009 6 91 17 (19) 81  7 39 (43) 16  9 ND 25 (28) 13 (15) 5 (6)
Rodés-Cabau et al. (27) 2010 Obs.
(multi.)
Canada Jan. 2005–June 2009 8 339 17 (5) 81  8 152 (45) ND 10  6 115 (34) ND ND
Roten et al. (28) 2010 Obs.
(single)
Switzerland Aug. 2007–Dec. 2008 2.6 67 23 (34) 83 (80-85) 31 (46) 23 (13-34) 6 (4-9) 8 (12) 11 (16) 13 (19)
Thomas et al. (29) 2010 Obs.
(multi.)
Europe Nov. 2007–Jan. 2009 1 1,038 73 (7) 81  9 463 (45) 27  22 ND ND ND ND
Bosmans et al. (30) 2011 Obs.
(multi.)
Belgium Until April 2010 1 328 40 (12) 83  6 151 (46) 28  16 ND 30 (9) ND ND
D’Ancona et al. (31) 2011 Obs.
(single)
Germany April 2008–March 2011 12 322 20 (6) 79  8 107 (33) 37  20 18  10 93 (29) ND ND
Ewe et al. (32) 2011 Obs.
(single)
Netherlands ND ND 104 4 (4) 81  8 52 (50) 21  12 9  4 22 (21) ND ND
Fraccaro et al. (33) 2011 Obs.
(single)
Italy May 2007–April 2009 6 64 25 (39) 81  7 29 (45) 24  15 ND 10 (16) 9 (14) 8 (13)
Guetta et al. (34) 2011 Obs.
(multi.)
Israel 2008–2010 3 70 28 (40) 83  5 26 (37) ND ND 19 (27) 17 (24) 11 (16)
Khawaja et al. (12) 2011 Obs.
(multi.)
UK April 2007–June 2009 ND 243 81 (33) 81  7 123 (51) ND ND 46 (19) 32 (13) 23 (10)
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TABLE 1 Continued
First Author (Ref. #) Year
Study
Design
(Centers) Region(s) Recruitment Period
Follow-Up
(Months)*
Sample
Size
Post-TAVR
PPM
Baseline Characteristics
Age
(yrs) Male
Log
EuroSCORE STS-PROM AF LBBB RBBB
Lefèvre et al. (35) 2011 Obs.
(multi.)
Europe April 2007–Jan. 2008 12 130 3 (2) 82  6 58 (45) 30  14 12  7 32 (25) ND ND
Akin et al. (36) 2012 Obs.
(single)
Germany Jan. 2007–Jan. 2008 0.2 45 23 (51) 81  6 18 (40) 21  16 ND 7 (16) 1 (2) 2 (4)
Bagur et al. (37) 2012 Obs.
(multi.)
Canada Jan. 2005–Aug. 2010 1 411 30 (7) 81  11 176 (43) 26  17 9  6 96 (23) 33 (8) 20 (5)
Calvi et al. (38) 2012 Obs.
(single)
Italy June 2007–April 2011 12 162 52 (32) 81  5 60 (40) 28  15 ND 27 (17) 5 (3) ND
Chorianopoulos
et al. (39)
2012 Obs.
(single)
Germany Jan. 2009–April 2011 1 130 46 (35) 81  6 54 (42) 24  13 ND 28 (22) 9 (7) 18 (14)
De Carlo et al. (40) 2012 Obs.
(multi.)
Italy Sept. 2007–July 2010 12 275 66 (24) 82  6 128 (47) 23  14 ND ND 37 (14) 32 (12)
Fraccaro et al. (41) 2012 Obs.
(multi.)
Italy June 2007–Dec. 2010 9 384 63 (16) 80  7 185 (48) 24  16 10  9 ND ND ND
Gilard et al. (42) 2012 Obs.
(multi.)
France Jan. 2010–Oct. 2011 3.8 3,107 495 (16) 83  7 1,630 (51) 22  14 14  12 820 (31) ND ND
Hayashida et al. (11) 2012 Obs.
(single)
France Oct. 2006–Dec. 2010 7 260 17 (7) 83  6 129 (50) 24  11 ND ND ND ND
Liang et al. (43) 2012 Obs.
(single)
New Zealand Aug. 2008–July 2011 21 53 5 (9) 80  7 30 (57) 26  16 6  3 17 (32) 8 (15) 5 (9)
Muñoz-García
et al. (44)
2012 Obs.
(single)
Spain April 2008–May 2011 ND 174 48 (28) 79  7 65 (37) 19  10 7  5 56 (32) 30 (17) 29 (17)
Saia et al. (45) 2012 Obs.
(multi.)
Italy Feb. 2008–Oct. 2010 1 60 17 (28) 82  6 26 (43) 23  13 9  7 ND 9 (15) 11 (18)
Salinas et al. (46) 2012 Obs.
(single)
Spain ND 1 130 3 (2) 84  ND 13 (38) 23  ND ND 17 (50) ND ND
Schroeter et al. (47) 2012 Obs.
(single)
Germany 2008–2009 ND 88 32 (36) 80  6 ND 23  12 ND 28 (32) 7 (8) 6 (7)
Stangl et al. (48) 2012 Obs.
(single)
Germany July 2009–July 2011 3 100 20 (20) 79  8 42 (42) 20  15 ND 19 (19) ND ND
Ledwoch et al. (49) 2013 Obs.
(multi.)
Germany Jan. 2009–June 2010 1 1,147 386 (34) 82  6 468 (41) 20  13 ND 277 (24) ND ND
Mouillet et al. (50) 2013 Obs.
(single)
France Dec. 2007–Jan. 2011 10 79 21 (27) 82  17 24 (31) 23  10 ND 20 (25) 16 (20) 7 (9)
Simms et al. (51) 2013 Obs.
(single)
UK May 2008–Dec. 2010 ND 100 17 (17) 81  6 48 (48) ND ND 29 (29) ND ND
van der Boon et al. (52) 2013 Obs.
(single)
Netherlands Nov. 2005–Feb. 2011 12 167 36 (22) 81  7 77 (46) 13 (8-19) ND 41 (25) 14 (8) 17 (10)
Values are n (%), mean  SD, or median (interquartile range) as appropriate. *Follow-up is reported as mean or median as given by the authors.
AF ¼ atrial ﬁbrillation; EuroSCORE ¼ European System for Cardiac Operative Risk Evaluation; LBBB ¼ left bundle branch block; multi. ¼multicenter; ND ¼ no data; Obs. ¼ observational; PPM ¼ permanent pacemaker; RBBB ¼ right bundle branch block; STS-PROM ¼
Society of Thoracic Surgeons Predicted Risk of Mortality; TAVR ¼ transcatheter aortic valve replacement; UK ¼ United Kingdom.
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134for eligibility (Fig. 1). Finally, we identiﬁed 235
studies that reported the incidence of PPM implan-
tation after TAVR, whereas 41 studies (9,11,12,15–52)
fulﬁlled our pre-speciﬁed inclusion criteria to be
considered in our analysis (Table 1).
S T UDY, P A R T I C I P A N T S , A ND P ROC EDU RA L
CHARACTERISTICS. All of the studies were observa-
tional, and most included patients who had under-
gone TAVR in a single center (26 of 41 studies;
63%) (Table 1). Three studies were conducted in
non-European countries (34,37,43). Studies were
published between 2009 and 2013, and patient
recruitment occurred between 2005 and 2011. Follow-
up varied from 0.2 to 12 months, although 1 study of
limited sample size reported mid-term follow-up to 21
months.
Overall, 11,210 patients were evaluated in 41
studies, and 1,917 (17%) received a PPM after TAVR.
The incidence of PPM implantation after the inter-
vention ranged from 2% to 51% in individual studies
(for MCRS, median 28% [interquartile range: 24% to
35%]; for ESV, 6% [interquartile range: 5% to 7%]).
The mean age ranged between 79 and 84 years, and
men and women were enrolled equally (46% and
54%, respectively). Pre-procedural risk was assessed
by the logistic EuroSCORE or the STS-PROM score in
the majority of studies, although in 4 studies, the
authors did not report any relevant information. In-
formation on rhythm and conductance disturbances
at baseline, such as AF, LBBB, or RBBB, was incom-
pletely recorded in 25% (1,998 of 8,101), 12% (348 of
2,964), and 10% (269 of 2,802) of the patients,
respectively.
The implanted devices and preferred access routes
that had been used in each study are summarized
in Table 2. MCRS was used exclusively in 18 studies
(n ¼ 2,356) and ESV in 10 (n ¼ 2,735), whereas both
prostheses were available in 13 studies (n ¼ 6,119).
No other devices were used. The transfemoral (73%)
or transapical (23%) approach was preferred over
others (4% for direct aortic or subclavian access).
Transcarotid valve implantation was not reported in
any of the included studies.
INDICATIONS FOR PPM IMPLANTATION. Indications
for PPM implantation varied across the studies
(Online Table 1). Complete AV block after TAVR was
the most commonly reported indication for perma-
nent pacing, whereas the authors did not report the
reason(s) for PPM implantation in 14 studies.
DATA SYNTHESIS. Fourteen different predictors
were eligible for the analysis (Table 3), and 2 or more
nonoverlapping datasets were available for 11 ofthem. The number of patients with PPM implantation
after TAVR (n ¼ 1,917) for each predictor of interest as
given in each study and enabled the calculation of
crude RRs is summarized in Online Table 2.
The aggregate risk of PPM implantation after
intervention in the overall population irrespective of
type of valve was increased in men compared
with women (RR: 1.23; 95% CI: 1.10 to 1.38) (Fig. 2,
Online Fig. 1). Baseline electrocardiographic changes,
ﬁrst-degree AV block (RR: 1.52; 95% CI: 1.15 to 2.01),
left anterior hemiblock (RR: 1.62; 95% CI: 1.17 to 2.25),
and RBBB (RR: 2.89; 95% CI: 2.36 to 3.54), as well as
intraprocedural AV block (RR: 3.49; 95% CI: 2.49 to
4.89), were signiﬁcantly associated with PPM im-
plantation. Statistical heterogeneity was low to
moderate, with I2 estimates ranging between 0% and
44%. Based on data derived from 9 studies, implan-
tation of MCRS was associated with a 2.5-fold
increased risk of PPM implantation compared with
ESV (RR: 2.54; 95% CI: 2.08 to 3.12) in the overall
population, with low statistical heterogeneity across
the studies (I2 of 14%). No difference in risk of PPM
implantation was identiﬁed for patients with AF,
LBBB, and preserved left ventricular ejection fraction
at baseline. Only single datasets were available for
advanced age (>80 years), left posterior hemiblock,
and prolonged PR interval (>200 ms), and no signiﬁ-
cant associations were found. In a sensitivity analysis
restricted to large studies of $200 patients (n ¼ 13
studies), results remained consistent with the main
ﬁndings (Online Table 3).
Male sex (RR: 1.29; 95% CI: 1.07 to 1.56), ﬁrst-
degree AV block (RR: 1.65; 95% CI: 1.22 to 2.23), left
anterior hemiblock (RR: 1.64; 95% CI: 1.13 to 2.40),
and RBBB (RR: 2.72; 95% CI: 2.14 to 3.45) remained
signiﬁcant predictors of PPM implantation when
only patients who received the MCRS bioprosthesis
were considered (Fig. 3, Online Fig. 2). I2 indicated
moderate heterogeneity only for RBBB (I2¼50%).
The summary point estimate suggested a lower
risk of permanent pacing with the transfemoral
access route (compared with trans-subclavian), but
the difference was not nominally signiﬁcant given
the sparse data (RR: 0.54; 95% CI: 0.28 to 1.04;
p ¼ 0.07).
Among the subgroup of patients with ESV im-
plantation, the available data for evaluation of the
selected predictors were limited. Sex (male), AF (at
baseline), and access route (transarterial vs. trans-
apical) did not appear to signiﬁcantly increase the
risk of PPM implantation (Fig. 4, Online Fig. 3), but
95% CIs were wide. Findings were based on datasets
from 2, 3, and 7 studies, respectively.
TABLE 2 Implanted Valves and Access Site Across Studies
First Author (Ref. #)
ESV MCRS
Any Femoral Apical Other* Any Femoral Apical Other*
Himbert et al. (15) 75 (100) 51 (68) 24 (32) No No No No No
Thielmann et al. (16) 39 (100) 15 (38) 24 (62) No No No No No
Attias et al. (17) 72 (87) 72 (87) No No 11 (13) 11 (13) No No
Bleiziffer et al. (18) 36 (23) 4 (3) 32 (20) No 123 (77) 112 (70) 5 (3)† 6 (4)
Eltchaninoff et al. (9) 166 (68) 95 (39) 71 (29) No 78 (32) 66 (27) No 12 (5)
Baan et al. (19) No No No No 29 (100) 29 (100) No No
Erkapic et al. (20) 14 (28) No 14 (28) No 36 (72) 36 (72) No No
Ewe et al. (21) 147 (100) 75 (51) 72 (49) No No No No No
Ferreira et al. (22) No No No No 32 (100) 32 (100) No No
Godino et al. (23) 79 (58) 61 (45) 15 (11) 3 (2) 28 (43) 16 (34) No 12 (9)
Haworth et al. (24) No No No No 33 (100) 33 (100) No No
Petronio et al. (25) No No No No 514 (100) 460 (89) No 54 (11)
Piazza et al. (26) No No No No 91 (100) 91 (100) No No
Rodés-Cabau et al. (27) 339 (100) 162 (48) 177 (52) No No No No No
Roten et al. (28) 26 (39) 9 (14) 17 (25) No 41 (61) 41 (61) No No
Thomas et al. (29) 1,038 (100) 463 (45) 575 (55) No No No No No
Bosmans et al. (30) 187 (57) 99 (30) 88 (27) No 141 (43) 133 (41) No 8 (2)
D’Ancona et al. (31) 322 (100) No 322 (100) No No No No No
Ewe et al. (32) 104 (100) 45 (43) 59 (57) No No No No No
Fraccaro et al. (33) No No No No 64 (100) 60 (94) No 4 (6)
Guetta et al. (34) No No No No 70 (100) 70 (100) No No
Khawaja et al. (12) No No No No 243 (100)‡ ND No ND
Lefèvre et al. (35) 130 (100) 69 (53) 61 (47) No No No No No
Akin et al. (36) No No No No 45 (100) 45 (100) No No
Bagur et al. (37) 411 (100) 223 (54) 188 (46) No No No No No
Calvi et al. (38) No No No No 162 (100) 162 (100) No No
Chorianopoulos et al. (39) No No No No 130 (100) 130 (100) No No
De Carlo et al. (40) No No No No 275 (100)‡ ND No ND
Fraccaro et al. (41) ND§ ND ND ND ND§ ND ND ND
Gilard et al. (42) 2,107 (67) ND ND ND 1,043 (33) ND ND ND
Hayashida et al. (11) 222 (85) 138 (53) 83 (31) 1 (1) 38 (15) 31 (12) No 7 (3)
Liang et al. (43) 15 (28) 9 (17) 6 (11) No 38 (72) 38 (72) No No
Muñoz-García et al. (44) No No No No 174 (100) 156 (90) No 18 (10)
Saia et al. (45) No No No No 60 (100) 49 (82) No 11 (18)
Salinas et al. (46) 34 (100) 31 (91) 3 (9) No No No No No
Schroeter et al. (47) No No No No 88 (100) 88 (100) No No
Stangl et al. (48) 17 (17) 17 (17) No No 83 (83) 83 (83) No No
Ledwoch et al. (49) 232 (20) ND ND ND 915 (80) ND ND ND
Mouillet et al. (50) No No No No 79 (100) 79 (100) No No
Simms et al. (51) No No No No 100 (100) 100 (100) No No
van der Boon et al. (52) No No No No 167 (100) 162 (97) No 5 (3)
Values are n (%). *Including transaortic and/or trans-subclavian access. †Authors reported that transapical implantation of the MCRS was approved by the institutional ethics committee.
‡Transfemoral and subclavian access were used. §Both bioprostheses were implanted via an arterial retrograde (transfemoral, trans-subclavian, or transaortic) approach or via an antegrade
transapical approach. The authors did not provide further details.
ESV ¼ Edwards SAPIEN Valve; MCRS ¼ Medtronic CoreValve Revalving System; ND ¼ no data.
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135DISCUSSION
Our ﬁndings suggest that male sex, pre-procedural
evidence of abnormal AV conduction (including
ﬁrst-degree AV block, left anterior hemiblock, and
RBBB), and intraprocedural AV block indicate an
increased risk of PPM implantation after TAVRfor patients receiving any type of prosthesis,
although the risk of PPM implantation was 2.5-fold
higher in patients receiving the MCRS than in
those receiving the ESV in an unadjusted analysis.
These variables remained signiﬁcant predictors of
permanent pacing among patients with MCRS
bioprosthesis.
TABLE 3 Extracted Predictors Across Studies
Predictor (Ref. #) Number of Studies
Age (>80 yrs) (49) 1
Sex (male) (11,18,19,28,31,33,36-38,40,44,45,48–52) 17
Atrial ﬁbrillation (18–20,28,31,37–39,44,46,47,49–52) 15
First-degree AV block (9,18,37–40) 6
Left anterior hemiblock (20,37,38,40,52) 5
Left posterior hemiblock (52) 1
Intraprocedural AV block (18,44) 2
LBBB (9,12,18–20,24,28,37–40,44,45,47,50,52) 16
RBBB (12,18–20,22,24,26,28,34,37,39,40,44,45,47,50,52) 17
PR interval (>200 ms) (20) 1
MCRS (vs. ESV) (17,18,20,23,28,30,42,43,49) 9
Preserved LVEF (21,41,44,51) 4
Access route (arterial vs. apical): ESV (9,15,16,27–29,32,35,37) 9
Access route (femoral vs. subclavian): MCRS (25,33,45) 3
AV ¼ atrioventricular; ESV ¼ Edwards SAPIEN Valve; LBBB ¼ left bundle branch block; LVEF ¼
left ventricular ejection fraction; MCRS ¼ Medtronic CoreValve Revalving system; RBBB ¼ right
bundle branch block.
Predictor
No. of
participants
Any va
No. of
studies
Age>80 1 1,147
3,621
3,215
1,381
1,065
167
333
2,371
2,158
50
5,131
805
0.2 0.5
Decreased Risk
17
15
6
5
1
2
16
17
1
9
4
Sex (male)
Atrial fibrillation
First-degree AV block
Left anterior hemiblock
Left posterior hemiblock
Intraoperative AV block
LBBB
RBBB
PR>200 msec
MCRS (versus ESV)
Preserved LVEF
FIGURE 2 Summary RRs for Each Predictor of PPM Implantation Af
Forest plot of summary crude risk ratios (RRs) of each assessed predicto
(MCRS) or Edwards SAPIEN valve (ESV) prosthesis. Heterogeneity estim
more studies were available. AV ¼ atrioventricular; CI ¼ conﬁdence inter
fraction; PPM ¼ permanent pacemaker; RBBB ¼ right bundle branch blo
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136Identiﬁcation of patients at increased risk of PPM
implantation after TAVR is of great clinical impor-
tance to prevent AV-block–related complications,
including syncope, exercise intolerance, heart fail-
ure, and sudden death. As previously demonstrated,
patients with AV conduction disturbances after
TAVR are prone to prolonged hospitalization and
use of in-hospital continuous telemetry, both of
which result in a considerable increase of overall
cost of the TAVR procedure (53). Moreover, there
are concerns that patients who require PPM may
not derive the same beneﬁt as patients without PPM
because of loss of AV synchrony, lack of physio-
logical rate control, and right ventricular stimula-
tion (54,55).
Evidence of sex-related differences in survival
and common complications after TAVR intervention
has been conﬂicted in recently published studies
(56–58). In the present report, men had a higher risk
for PPM implantation. Male patients undergoing
TAVR tend to have more comorbidities and higherRR (95% CI) p-value I-squared
lve
1.17 0.09 -
0%
0%
0%
44%
14%
12%
-
-
-
25%
4%
<0.01
<0.01
0.12
0.91
0.93
0.42
0.35
<0.01
<0.01
<0.01
<0.01
(0.98-1.41)
(1.10-1.38)
(0.96-1.41)
(1.15-2.01)
(1.17-2.25)
(0.10-12.83)
(2.49-4.89)
(0.80-1.27)
(2.36-3.54)
(0.59-3.62)
(2.08-3.12)
(0.78-2.02)
1.23
1.16
1.52
1.62
1.14
3.49
1.01
2.89
1.45
2.54
1.26
Increased Risk
1 2 5
ter TAVR (Any Valve)
r for patients receiving the Medtronic CoreValve Revalving System
ates (I2) are given for those predictors for which datasets from 2 or
val; LBBB ¼ left bundle branch block; LVEF ¼ left ventricular ejection
ck; TAVR ¼ transcatheter aortic valve replacement.
MCRS
Predictor RR (95% CI) p-value I-squared
No. of
participants
No. of
studies
Sex (male) 10 1,155 1.29 (1.07-1.56) <0.01 0%
0%
0%
-
-
0%
50%
41%
67%
47%
<0.01
<0.01
<0.01
0.01
0.91
0.77
0.87
0.07
0.15(0.92-1.77)
(1.22-2.23)
(1.13-2.40)
(0.10-12.83)
(2.27-5.34)
(0.80-1.35)
(2.14-3.45)
(0.19-4.14)
(0.28-1.04)
1.28
1.65
1.64
1.14
3.48
1.04
2.72
0.88
0.54
929
567
604
167
174
1,440
1,471
274
638
8
3
3
1
1
11
13
2
3
First-degree AV block
Left anterior hemiblock
Left posterior hemiblock
Intraoperative AV block
LBBB
RBBB
Preserved LVEF
Access route (femoral vs. subclavian)
Atrial fibrillation
0.2 0.5
Decreased Risk Increased Risk
1 2 5
FIGURE 3 Summary RRs for Each Predictor of PPM Implantation After TAVR (MCRS Only)
Forest plot of summary crude RRs of each assessed predictor for patients receiving the MCRS prosthesis. Heterogeneity estimates (I2) are given
for those predictors for which datasets from 2 or more studies were available. Abbreviations as in Figure 2.
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137procedural risks, although they also receive larger
bioprostheses, which may have an impact on AV
conduction (11,58).
Previous studies have documented a signiﬁcant
increase in the frequency of LBBB after TAVR,
which indicates direct injury of the intraventricular
conduction system during valve implantation
(59,60). As a result, any additional damage to the
conduction system in patients with AV conduction
abnormalities before intervention may lead to com-
plete AV block. In our meta-analysis, patients with
RBBB, ﬁrst-degree AV block, or left anterior hemi-
block at baseline were at higher risk for PPM im-
plantation after the intervention. AV conduction
disturbances and a subsequent requirement for PPM
are more common after MCRS than ESV implantation
(4,59), an observation from single studies that was
validated in our meta-analysis. The increased risk of
AV block with MCRS has been attributed to the valve
design (self-expanding vs. balloon-expandable) and
the potential of a deeper implantation into the left
ventricular outﬂow tract. This may result in moreinjury to the AV node and left bundle branches,
which may be delayed because of the self-expanding
nature of the prosthesis and tissue edema (12).
The reported indications for permanent pacing
were inconsistent across the studies, resulting in
a lack of consensus for early PPM implantation
after TAVR. Although PPM is indicated for asymp-
tomatic patients with acquired third- or second-
degree type 2 AV block (61), absolute and relative
indications for TAVR patients have not been estab-
lished. In patients with aortic stenosis and severe
comorbidities undergoing TAVR, a somewhat more
aggressive approach may have been adopted,
although a proportion of AV conduction disturbances
after the intervention have been shown to recover
over time (10,34,62). Currently, consensus statements
suggest continuous post-procedural monitoring in
all patients early after TAVR, although high-risk
patients (as deﬁned by pre-existing or new AV con-
duction abnormalities) may require longer moni-
toring (2). As a consequence, a proportion of patients
may have unnecessarily undergone “prophylactic”
ESV
Sex (male) 2 0%
0%
-
-
-
-
0%
-
0.45
0.34
0.28
0.51
0.35
0.38
0.89
<0.01
1.23 (0.72-2.11)
(0.36-1.41)
(0.05-2.42)
(0.47-4.54)
(0.06-2.81)
(2.91-12.19)
(0.05-3.07)
(0.64-1.25)
0.72
0.34
0.39
1.46
5.95
0.38
0.89
733
863
411
411
411
411
147
2,136
3
1
1
1
1
1
7
First-degree AV block
Left anterior hemiblock
LBBB
RBBB
Preserved LVEF
Access route (arterial vs. apical)
Atrial fibrillation
Predictor RR (95% CI) p-value I-squared
No. of
participants
No. of
studies
0.2 0.5
Decreased Risk Increased Risk
1 2 5
FIGURE 4 Summary RRs for Each Predictor of PPM Implantation After TAVR (ESV Only)
Forest plot of summary crude RRs of each assessed predictor for patients receiving the ESV prosthesis. Heterogeneity estimates (I2) are given
for those predictors for which datasets from 2 or more studies were available. Abbreviations as in Figure 2.
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138PPM implantation in the absence of an absolute
indication.
STUDY LIMITATIONS. Several limitations should
be acknowledged. We looked into a considerable
number of clinically meaningful variables, but we
did not aim to systematically examine all recently
discussed predictors. However, even among the
selected predictors, the available data were sparse.
Long-term follow-up data were not reported in
the majority of the studies, and clinical outcomes
related to PPM also were missing. Thus, we could
not address the clinical long-term effectiveness
of PPM implantation in these high-risk patients.
PPM implantation after TAVR does not represent a
surrogate marker of AV conduction disturbances
but may be inﬂuenced by several logistic and eco-
nomic factors that were not addressed in our anal-
ysis. Finally, adjusted estimates were unavailable
for most of the predictors, and we used crude RRs
only. Confounding could therefore have inﬂuenced
our results, and we were unable to determine the
independent role of individual predictors after
appropriate adjustment.CONCLUSIONS
The present study provides evidence for a number of
variables that serve as predictors of PPM implanta-
tion after TAVR in high-risk patients receiving 1 of
the 2 most widely used devices. Future research
should focus on collaborative efforts to validate
previously identiﬁed predictors and to explore the
role of others, and well-designed large-scale studies
that include different devices should focus on long-
term clinical outcomes. Given the clinical and eco-
nomic impact of such interventions (53,63), clinicians
should appropriately risk-stratify patients. Well-
established predictors can be useful tools to guide
clinical decision making before and after TAVR
(appropriate device selection and decision for per-
manent pacing, respectively) and subsequently
improve clinical outcomes.
REPRINT REQUESTS AND CORRESPONDENCE TO: Dr
Stephan Windecker, Department of Cardiology, Bern
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE 1: Indica-
tions for permanent pacing in patients undergoing TAVR
have not been clearly established, and criteria have varied
across studies.
COMPETENCY IN MEDICAL KNOWLEDGE 2: Male
sex, abnormal AV conduction before the procedure, and
intraprocedural AV block identify patients more likely to
require PPM implantation after TAVR with the Edwards
SAPIEN or Medtronic CoreValve prosthesis.
COMPETENCY IN PATIENT CARE: Identiﬁcation of
patients at increased risk for PPM implantation after
TAVR is of great clinical importance to reduce the length
of hospitalization and to prevent complications related to
AV-block conduction disturbances.
TRANSLATIONAL OUTLOOK: Better understanding
of the factors that lead to development of complete heart
block among patients undergoing TAVR could identify
appropriate candidates for prophylactic permanent
pacemaker implantation and improve clinical outcomes.
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